118 related articles for article (PubMed ID: 10678105)
1. CYP2D6 phenotype determines pharmacokinetic variability of propafenone enantiomers in 16 HAN Chinese subjects.
Cai WM; Chen B; Cai MH; Zhang YD
Zhongguo Yao Li Xue Bao; 1999 Aug; 20(8):720-4. PubMed ID: 10678105
[TBL] [Abstract][Full Text] [Related]
2. The influence of CYP2D6 activity on the kinetics of propafenone enantiomers in Chinese subjects.
Cai WM; Chen B; Cai MH; Chen Y; Zhang YD
Br J Clin Pharmacol; 1999 May; 47(5):553-6. PubMed ID: 10336580
[TBL] [Abstract][Full Text] [Related]
3. Fluoxetine impairs the CYP2D6-mediated metabolism of propafenone enantiomers in healthy Chinese volunteers.
Cai WM; Chen B; Zhou Y; Zhang YD
Clin Pharmacol Ther; 1999 Nov; 66(5):516-21. PubMed ID: 10579479
[TBL] [Abstract][Full Text] [Related]
4. Influence of CYP2D6*10B genotype on pharmacokinetics of propafenone enantiomers in Chinese subjects.
Chen B; Cai WM
Acta Pharmacol Sin; 2003 Dec; 24(12):1277-80. PubMed ID: 14653957
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous modeling of pharmacokinetics and pharmacodynamics of propafenone in healthy subjects.
Cai WM; Zhang YD; Chen B; Cai MH; Luo JP; Ling SS
Acta Pharmacol Sin; 2001 Oct; 22(10):956-60. PubMed ID: 11749782
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic and pharmacodynamic interaction between mexiletine and propafenone in human beings.
Labbé L; O'Hara G; Lefebvre M; Lessard E; Gilbert M; Adedoyin A; Champagne J; Hamelin B; Turgeon J
Clin Pharmacol Ther; 2000 Jul; 68(1):44-57. PubMed ID: 10945315
[TBL] [Abstract][Full Text] [Related]
7. The influence of CYP2D6 polymorphism on the antiarrhythmic efficacy of propafenone in patients with paroxysmal atrial fibrillation during 3 months propafenone prophylactic treatment.
Jazwinska-Tarnawska E; Orzechowska-Juzwenko K; Niewinski P; Rzemislawska Z; Loboz-Grudzien K; Dmochowska-Perz M; Slawin J
Int J Clin Pharmacol Ther; 2001 Jul; 39(7):288-92. PubMed ID: 11471772
[TBL] [Abstract][Full Text] [Related]
8. Use of a propafenone metabolic ratio as a measure of CYP2D6 activity.
Anzenbacherová E; Anzenbacher P; Perlik F; Kvetina J
Int J Clin Pharmacol Ther; 2000 Sep; 38(9):426-9. PubMed ID: 11020029
[TBL] [Abstract][Full Text] [Related]
9. Effect of CYP2D6 polymorphisms on the pharmacokinetics of propafenone and its two main metabolites.
Rouini MR; Afshar M
Therapie; 2017 Jun; 72(3):373-382. PubMed ID: 28087064
[TBL] [Abstract][Full Text] [Related]
10. Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolizers of CYP2D6.
Dilger K; Greiner B; Fromm MF; Hofmann U; Kroemer HK; Eichelbaum M
Pharmacogenetics; 1999 Oct; 9(5):551-9. PubMed ID: 10591535
[TBL] [Abstract][Full Text] [Related]
11. Effect of
Doki K; Shirayama Y; Sekiguchi Y; Aonuma K; Kohda Y; Ieda M; Homma M
Pharmacogenomics; 2020 Dec; 21(18):1279-1288. PubMed ID: 33203295
[No Abstract] [Full Text] [Related]
12. Stereoselective steady state disposition and action of propafenone in Chinese subjects.
Li G; Gong PL; Qiu J; Zeng FD; Klotz U
Br J Clin Pharmacol; 1998 Nov; 46(5):441-5. PubMed ID: 9833596
[TBL] [Abstract][Full Text] [Related]
13. Effect of CYP2D6*10 genotype on propafenone pharmacodynamics in Chinese patients with ventricular arrhythmia.
Cai WM; Xu J; Chen B; Zhang FM; Huang YZ; Zhang YD
Acta Pharmacol Sin; 2002 Nov; 23(11):1040-4. PubMed ID: 12421483
[TBL] [Abstract][Full Text] [Related]
14. Concentration dependent stereoselectivity of propafenone N-depropylation metabolism with human hepatic recombinant CYP1A2.
Zhou Q; Yao TW; Yu YN; Zeng S
Pharmazie; 2003 Sep; 58(9):651-3. PubMed ID: 14531463
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of CYP2D6 oxidation of dextromethorphan and propafenone in a Chinese population with atrial fibrillation.
Chow MS; White CM; Lau CP; Fan C; Tang MO
J Clin Pharmacol; 2001 Jan; 41(1):92-6. PubMed ID: 11144999
[TBL] [Abstract][Full Text] [Related]
16. Disposition of propafenone in a poor metabolizer of CYP2D6 with Gilbert's syndrome.
Dilger K; Meisel P; Hofmann U; Eichelbaum M
Ther Drug Monit; 2000 Jun; 22(3):366-8. PubMed ID: 10850406
[TBL] [Abstract][Full Text] [Related]
17. Application of a physiologically based pharmacokinetic model for the evaluation of single-point plasma phenotyping method of CYP2D6.
Chen R; Rostami-Hodjegan A; Wang H; Berk D; Shi J; Hu P
Eur J Pharm Sci; 2016 Sep; 92():131-6. PubMed ID: 27412587
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of tramadol enantiomers and their respective phase I metabolites in relation to CYP2D6 phenotype.
García-Quetglas E; Azanza JR; Sádaba B; Muñoz MJ; Gil I; Campanero MA
Pharmacol Res; 2007 Feb; 55(2):122-30. PubMed ID: 17175164
[TBL] [Abstract][Full Text] [Related]
19. Assessment of 25 CYP2D6 alleles found in the Chinese population on propafenone metabolism in vitro.
Su Y; Liang BQ; Feng YL; Zhan Y; Gu E; Chen X; Dai DP; Hu GX; Cai JP
Can J Physiol Pharmacol; 2016 Aug; 94(8):895-9. PubMed ID: 27203132
[TBL] [Abstract][Full Text] [Related]
20. Effect of CYP2D6 metabolizer status on the disposition of the (+) and (-) enantiomers of perhexiline in patients with myocardial ischaemia.
Inglis SC; Herbert MK; Davies BJ; Coller JK; James HM; Horowitz JD; Morris RG; Milne RW; Somogyi AA; Sallustio BC
Pharmacogenet Genomics; 2007 May; 17(5):305-12. PubMed ID: 17429312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
